Magle Chemoswed Holding AB Logo

Magle Chemoswed Holding AB

A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.

MAGLE | ST

Overview

Corporate Details

ISIN(s):
SE0014401014 (+2 more)
LEI:
549300FNJZS6NGFB6M31
Country:
Sweden
Address:
Agneslundsvägen 27, 212 15 Malmö
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Magle Chemoswed Holding AB is a contract development and manufacturing organization (CDMO) that serves companies in the pharmaceutical and medical device industries. The company offers a comprehensive suite of services that guide innovations from idea to finished product. Core capabilities include analytical and process development, solid-state chemistry, and specialized manufacturing. Its manufacturing services are performed in a cGMP and ISO 13485 compliant facility and include lyophilization (freeze-drying), flexible small-scale vial filling and finishing, and support for inhalation drug delivery systems. Magle Chemoswed partners with clients to provide end-to-end support for product development and manufacturing on a contract basis.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Magle Chemoswed Holding AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Magle Chemoswed Holding AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Magle Chemoswed Holding AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-01-21 Stig Lökke Pedersen Other Other 384,000 11,520,000.00 SEK
2024-12-11 Martin Lidgard Other Buy 4,211 136,436.40 SEK
2024-12-05 Martin Lidgard Other Buy 632 21,740.80 SEK
2024-12-02 Martin Lidgard Other Buy 5,000 163,900.00 SEK

Peer Companies

Company Country Ticker View
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America ADCT
Addex Therapeutics Ltd. Logo
Developing novel oral allosteric modulators to treat neurological disorders.
United States of America ADXN
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America ADIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.